• Exelixis Inc., of South San Francisco, reported preliminary data from a Phase Ib drug interaction trial of cabozantinib in renal cell carcinoma, showing a high rate of durable tumor response, with a low rate of primary refractoriness to drug therapy, and a long median progression-free survival.
Sign up for Perspectives FREE e-mail newsletter.
Outside the U.S.: 1-404-262-5423
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST